Advertisement
Canada markets open in 8 hours 29 minutes
  • S&P/TSX

    22,346.76
    -121.40 (-0.54%)
     
  • S&P 500

    5,307.01
    -14.40 (-0.27%)
     
  • DOW

    39,671.04
    -201.95 (-0.51%)
     
  • CAD/USD

    0.7308
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    77.02
    -0.55 (-0.71%)
     
  • Bitcoin CAD

    95,107.88
    -120.57 (-0.13%)
     
  • CMC Crypto 200

    1,514.85
    -11.56 (-0.76%)
     
  • GOLD FUTURES

    2,375.60
    -17.30 (-0.72%)
     
  • RUSSELL 2000

    2,081.71
    -16.65 (-0.79%)
     
  • 10-Yr Bond

    4.4340
    +0.0200 (+0.45%)
     
  • NASDAQ futures

    18,966.25
    +179.50 (+0.96%)
     
  • VOLATILITY

    12.29
    +0.43 (+3.63%)
     
  • FTSE

    8,370.33
    -46.12 (-0.55%)
     
  • NIKKEI 225

    39,101.27
    +484.17 (+1.25%)
     
  • CAD/EUR

    0.6748
    +0.0003 (+0.04%)
     

WELL Health Technologies First Quarter 2024 Earnings: Beats Expectations

WELL Health Technologies (TSE:WELL) First Quarter 2024 Results

Key Financial Results

  • Revenue: CA$231.6m (up 37% from 1Q 2023).

  • Net income: CA$15.1m (up from CA$14.4m loss in 1Q 2023).

  • Profit margin: 6.5% (up from net loss in 1Q 2023).

  • EPS: CA$0.062 (up from CA$0.062 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

WELL Health Technologies Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Healthcare industry in Canada.

ADVERTISEMENT

Performance of the Canadian Healthcare industry.

The company's shares are up 10% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with WELL Health Technologies, and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.